Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
March 2018
-
Key ReleaseNovartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic prioritiesPrice reflects an attractive value to Novartis Proceeds to be used according to capital allocation priorities, including bolt-on acquisitions Sale of JV in a non-core segment in best long-term…
-
Key ReleaseNovartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrierenPreis stellt für Novartis einen attraktiven Wert dar Verkaufserlös wird in Übereinstimmung mit den Prioritäten für die Kapitalallokation verwendet, einschliesslich für Bolt-on-Akquisitionen Verkauf…
-
Media ReleaseSandoz receives positive CHMP opinion for proposed biosimilar infliximabSandoz is seeking approval of biosimilar infliximab for use in all indications of its reference medicine across gastroenterology, rheumatology and dermatology Positive opinion is based on a…
-
Malaria is still disrupting lives, despite progress
The disease hobbles families and economies.
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MSEXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical secondary progressive MS (SPMS) patients Results demonstrate…
-
Media ReleaseNovartis drug Tasigna® approved by FDA to treat children with rare form of leukemiaTasigna® (nilotinib) approved for pediatric patients with newly diagnosed Ph+ CML-CP and children with Ph+ CML-CP resistant or intolerant to prior TKI therapy New indication approved under FDA…
-
Building “boot camps” for immune cells near tumors
Bioengineers, immunologists and clinicians collaborate to explore a new approach to fighting cancer.
-
Media ReleaseNovartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapiesCollaboration and licensing agreement combine Harvard's expertise in tumor biology and materials science with Novartis' diverse immuno-oncology pipeline Teams will explore the development…
-
Featured NewsNovartis Foundation joins Global Partnership for Zero Leprosy
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.
-
Media ReleaseAveXis Enters into Licensing Agreement with GenethonIncludes exclusive worldwide rights to AAV9-SMN product and route of administration CHICAGO and ÉVRY, France, March 13, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) and Genethon today…
-
Key ReleaseNovartis announces changes to the Executive Committee to support strategic prioritiesBertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN) Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN Shannon Klinger…
-
Key ReleaseNovartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten anBertrand Bodson, Chief Digital Officer, wird in die Geschäftsleitung von Novartis berufen Steffen Lang, Global Head Novartis Technical Operations, wird in die Geschäftsleitung von Novartis berufen…
Pagination
- ‹ Previous page
- 1
- …
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- …
- 151
- › Next page